Navigation Links
Katie Hood Appointed Chief Executive Officer of The Michael J. Fox Foundation
Date:12/14/2007

- Key Architect of Foundation's Strategy Will Build On and Expand Transformational Approach -

NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced the appointment of Katie Hood as chief executive officer.

Ms. Hood, who joined the Foundation in September 2002, has been serving as interim CEO since October. As chief executive officer, she will build on the Foundation's strategy of inserting itself proactively into the research process to advance scientific breakthroughs, including the expansion of current initiatives to:

-- validate promising drug targets, thereby opening new opportunities for drug development;

-- increase investment in various stages of pre-clinical research and chaperoning pre-clinical hits from stage to stage;

-- selectively support clinical projects with the potential to improve patients' lives in the near-term; and

-- drive high-risk, high-reward attempts to uncover new research tools such as biomarkers.

Ms. Hood stated, "The Michael J. Fox Foundation has evolved into an organization willing to do whatever it takes to accelerate life-transforming treatments for Parkinson's patients - going beyond innovative funding mechanisms to work to change a flawed system that too often fails to translate research into results. Over the past seven years, we have built a unique expertise about Parkinson's research that we intend to leverage for impact over the coming months and years. Our capital should be -- and will be -- used to drive progress in ways that other funding sources are not."

David Golub, chairman of the Board of Directors of The Michael J. Fox Foundation, said: "We are committed to a strategy of working relentlessly to close critical gaps in the process of moving potential treatments from the laboratory to Parkinson's patients, and have worked with Katie and the entire executive team to develop a compelling vision of how that approach should be enhanced and extended for greater impact. The Board is confident that Katie is the right person to lead the MJFF forward and is sure that our efforts will result in scientific breakthroughs that ultimately translate into novel and effective therapies."

Ms. Hood will continue to provide day-to-day management and oversight of all Foundation activities and will specifically oversee fundraising, the Foundation's research team and communications, administration and financial management. Ms. Hood will report to the Board of Directors.

Before October of this year, Ms. Hood had served as deputy CEO of MJFF and, earlier, as vice president of research programs. Prior to joining the Foundation, Ms. Hood was employed as a consultant at Bain & Company in New York City, doing work in the consumer products, financial services, and nonprofit sectors. She has also served as an analyst in the Credit Department of Goldman, Sachs & Co., and as a program coordinator with Duke University's Hart Leadership Program. Ms. Hood graduated from Harvard Business School and holds a BA in Public Policy Studies from Duke University in Durham, North Carolina. A full biosketch is available at http://www.michaeljfox.org.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded $100 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Katie Lee Joel to Conduct Cooking Demonstration for Local Patients With Chronic Kidney Disease
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
4. William Moore Appointed to IRIDEX Board of Directors
5. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
6. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
7. James B. Hawkins Appointed to IRIDEX Board of Directors
8. Bryan R. Rogers Appointed President of Far West Division
9. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
10. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
11. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: